Stock Research for OCUL

OCUL

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

OCUL Stock Chart & Research Data

The OCUL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the OCUL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


OCUL Due diligence Resources & Stock Charts

The OCUL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View OCUL Detailed Price Forecast - CNN Money CNN View OCUL Detailed Summary - Google Finance
Yahoo View OCUL Detailed Summary - Yahoo! Finance Zacks View OCUL Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View OCUL Trends & Analysis - Trade-Ideas Barrons View OCUL Major Holders - Barrons
NASDAQ View OCUL Call Transcripts - NASDAQ Seeking View OCUL Breaking News & Analysis - Seeking Alpha
Spotlight View OCUL Annual Report - CompanySpotlight.com OTC Report View OCUL OTC Short Report - OTCShortReport.com
TradeKing View OCUL Fundamentals - TradeKing Charts View OCUL SEC Filings - Bar Chart
WSJ View Historical Prices for OCUL - The WSJ Morningstar View Performance/Total Return for OCUL - Morningstar
MarketWatch View the Analyst Estimates for OCUL - MarketWatch CNBC View the Earnings History for OCUL - CNBC
StockMarketWatch View the OCUL Earnings - StockMarketWatch MacroAxis View OCUL Buy or Sell Recommendations - MacroAxis
Bullish View the OCUL Bullish Patterns - American Bulls Short Pains View OCUL Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View OCUL Stock Mentions - StockTwits PennyStocks View OCUL Stock Mentions - PennyStockTweets
Twitter View OCUL Stock Mentions - Twitter Invest Hub View OCUL Investment Forum News - Investor Hub
Yahoo View OCUL Stock Mentions - Yahoo! Message Board Seeking Alpha View OCUL Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for OCUL - SECform4.com Insider Cow View Insider Transactions for OCUL - Insider Cow
CNBC View OCUL Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for OCUL - OTC Markets
Yahoo View Insider Transactions for OCUL - Yahoo! Finance NASDAQ View Institutional Holdings for OCUL - NASDAQ


Stock Charts

FinViz View OCUL Stock Insight & Charts - FinViz.com StockCharts View OCUL Investment Charts - StockCharts.com
BarChart View OCUL Stock Overview & Charts - BarChart Trading View View OCUL User Generated Charts - Trading View




Latest Financial News for OCUL


2 Small-Cap Growth Stocks With Room to Run
Posted on Wednesday April 24, 2024

These two small-cap growth stocks could be ready to run.


Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder
Posted on Thursday April 18, 2024

On Thursday, Ocular Therapeutix Inc (NASDAQ:OCUL) announced topline results from the Phase 1 HELIOS study evaluating Axpaxli versus sham control in patients with moderately severe to severe non-proliferative diabetic retinopathy without diabetic macular edema (DME). 6 of 13 (46.2%) patients in the Axpaxli group experienced a 1 or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks, with 2 of the 6 having a 2-step improvement. No patients in the control group showed 1


Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
Posted on Thursday April 18, 2024

46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm No patients in the AXPAXLI group experienced worsening in DRSS compared to 12.5% in the control arm at 40 weeks AXPAXLI was generally well tolerated with no inflammation observed Ocular intends to present the Phase 1 HELIOS study at an upcoming meeting BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, In


The 3 Best Biotech Stocks to Buy Now: Q2 Edition
Posted on Tuesday April 16, 2024

Some of the hottest opportunities can be found in biotech stocks to buy now. With innovation, mergers and acquisitions, major companies looking to replenish their pipelines ahead of patent expirations, treatments for obesity, aging baby boomers, and demand for better care are creating massive opportunities. We’re even seeing big opportunities in cancer treatments known as ADCs (antibody-drug conjugates), and in gene-editing. We can even look at the impact artificial intelligence could have on he


Stock Market & Investing Books

Enter a stock symbol to view the stock details.